Loading organizations...
§ Private Profile · Cambridge, MA, USA
AI-driven SaaS platform for compliance and validation in regulated software development, accelerating product release.
Ketryx, based in Somerville, Massachusetts, develops an AI-driven platform that automates compliance, documentation, and validation for regulated software development. Integrating with DevTools, the platform streamlines processes for highly regulated industries such as medical devices, automotive, and aerospace. Its technology has supported products impacting 10 million patients, serving customers like DeepHealth, Heartflow, and three of the top five global medtech companies. The company has raised over $55 million in total funding, including a $39 million Series B led by Transformation Capital, with Lightspeed Venture Partners and MIT E14 Fund participating; Vinay Shah (Transformation Capital) joined the board. Ketryx was founded in 2021 by Erez Kaminski and Jan Poschko. Its business model centers on saaS platform for regulated industries, funded through venture capital rounds.
Ketryx has raised $53.0M across 2 funding rounds.
Ketryx has raised $53.0M in total across 2 funding rounds.
Ketryx has raised $53.0M across 2 funding rounds. Most recently, it raised $39.0M Series B in September 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2025 | $39M Series B | Transformation Capital, Vinay Shah | Benchmark, Lightspeed Venture Partners, MEI Z., William A. Hawkins, 53 Stations, Habib Haddad, Mitú, Ubiquity Ventures | Announced |
| Dec 1, 2023 | $14M Series A | Lightspeed Venture Partners | Benchmark, MEI Z., Habib Haddad, Mitú, Ubiquity Ventures | Announced |
Ketryx has raised $53.0M in total across 2 funding rounds.
Ketryx's investors include Transformation Capital, Vinay Shah, Benchmark, Lightspeed Venture Partners, Mei Z., William A. Hawkins, 53 Stations, Habib Haddad, MIT, Ubiquity Ventures.
Ketryx is an AI-powered lifecycle management platform designed for regulated medical applications, particularly in the healthcare technology sector. It provides FDA compliance software and application lifecycle management (ALM) tools for developing and deploying medical device software, including AI/ML components and Software as a Medical Device (SaMD).[1][2][3] The platform integrates with tools like Jira and GitHub, automating documentation, traceability, quality management system (QMS) processes, and risk management to enable faster releases while maintaining compliance.[1][3] Serving top medical device manufacturers and life sciences companies, Ketryx solves the paradox of regulated teams spending excessive time on manual documentation and compliance instead of innovation, achieving up to 10x faster release cycles, significant reductions in documentation time, and hours saved per developer annually.[2][3] Its growth is tied to improving patient outcomes, with a goal to help 100 million patients access superior medical care in five to seven years.[2]
Ketryx was founded in 2021 in Somerville, Massachusetts, by Erez Kaminski (CEO) and Jan Poschko (CTO), who bonded over their passion for innovation in biomedical hubs like Kendall Square.[1][2][4] The idea emerged during a dinner discussion: enabling developers in highly regulated industries to release safe, high-quality software at the speed of unregulated ones.[2] They assembled a world-class team, including John Koontz (former VP of Engineering at Wolfram Research) and Paul Jones (former head of FDA's Software Engineering Lab), to build a self-correcting platform that eliminates human error and enforces QMS procedures.[2] Early traction came from addressing pain points like manual documentation and fragmented systems, resulting in a connected platform that automates FDA-compliant outputs directly in preferred DevTools.[2]
Ketryx stands out in the MedTech compliance space through these key strengths:
Ketryx rides the convergence of AI adoption in MedTech and escalating regulatory demands for software in medical devices, where traditional processes slow innovation amid rising SaMD and AI/ML deployments.[1][2] Timing is ideal as FDA guidelines evolve for AI tools, creating urgency for compliant acceleration—Ketryx bridges development speed with safety, countering fragmented systems that bog down R&D.[3] Market forces like high-volume care needs and audit pressures favor it, influencing the ecosystem by enabling faster patient-impacting releases and setting a standard for agentic AI in regulated dev.[2][3] Competitors like Greenlight Guru focus on QMS but lack Ketryx's deep ALM integration and AI automation for software lifecycle.[1]
Ketryx is poised to dominate AI compliance in MedTech, expanding from top manufacturers to broader life sciences as AI validation mandates grow.[3] Upcoming trends like agentic AI proliferation and global harmonized regs (e.g., EU AI Act) will amplify its edge, potentially scaling to that 100-million-patient goal via platform enhancements and partnerships.[2] Its influence may evolve into an industry orchestrator, powering ecosystem-wide innovation while pre-IPO momentum from strong VCs signals robust growth.[4] This positions Ketryx as the compliant accelerator transforming how regulated software saves lives—bridging the speed-safety gap that sparked its founding.[2]